rs754504918

Variant summary

Our verdict is Uncertain significance. The variant received 0 ACMG points: 2P and 2B. PM2BP4_Moderate

The NM_000548.5(TSC2):​c.1979G>A​(p.Ser660Asn) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00000207 in 1,450,426 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. 15/22 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. S660C) has been classified as Uncertain significance.

Frequency

Genomes: not found (cov: 33)
Exomes 𝑓: 0.0000021 ( 0 hom. )

Consequence

TSC2
NM_000548.5 missense

Scores

5
14

Clinical Significance

Conflicting classifications of pathogenicity criteria provided, conflicting classifications U:4B:1

Conservation

PhyloP100: 2.88

Publications

1 publications found
Variant links:
Genes affected
TSC2 (HGNC:12363): (TSC complex subunit 2) This gene is a tumor suppressor gene that encodes the growth inhibitory protein tuberin. Tuberin interacts with hamartin to form the TSC protein complex which functions in the control of cell growth. This TSC protein complex negatively regulates mammalian target of rapamycin complex 1 (mTORC1) signaling which is a major regulator of anabolic cell growth. Mutations in this gene have been associated with tuberous sclerosis and lymphangioleiomyomatosis. [provided by RefSeq, May 2022]
TSC2 Gene-Disease associations (from GenCC):
  • tuberous sclerosis
    Inheritance: AD Classification: DEFINITIVE Submitted by: ClinGen
  • tuberous sclerosis 2
    Inheritance: AD Classification: DEFINITIVE, STRONG Submitted by: PanelApp Australia, Laboratory for Molecular Medicine, Labcorp Genetics (formerly Invitae), G2P, Genomics England PanelApp, Ambry Genetics
  • lymphangioleiomyomatosis
    Inheritance: AD Classification: STRONG Submitted by: Genomics England PanelApp
  • tuberous sclerosis complex
    Inheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Uncertain_significance. The variant received 0 ACMG points.

PM2
Very rare variant in population databases, with high coverage;
BP4
Computational evidence support a benign effect (MetaRNN=0.15011787).

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
TSC2NM_000548.5 linkc.1979G>A p.Ser660Asn missense_variant Exon 19 of 42 ENST00000219476.9 NP_000539.2 P49815-1

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
TSC2ENST00000219476.9 linkc.1979G>A p.Ser660Asn missense_variant Exon 19 of 42 5 NM_000548.5 ENSP00000219476.3 P49815-1

Frequencies

GnomAD3 genomes
Cov.:
33
GnomAD2 exomes
AF:
0.00
AC:
0
AN:
223734
AF XY:
0.00
Gnomad AFR exome
AF:
0.00
Gnomad AMR exome
AF:
0.00
Gnomad ASJ exome
AF:
0.00
Gnomad EAS exome
AF:
0.00
Gnomad FIN exome
AF:
0.00
Gnomad NFE exome
AF:
0.00
Gnomad OTH exome
AF:
0.00
GnomAD4 exome
AF:
0.00000207
AC:
3
AN:
1450426
Hom.:
0
Cov.:
32
AF XY:
0.00000139
AC XY:
1
AN XY:
720514
show subpopulations
African (AFR)
AF:
0.00
AC:
0
AN:
33240
American (AMR)
AF:
0.00
AC:
0
AN:
43700
Ashkenazi Jewish (ASJ)
AF:
0.00
AC:
0
AN:
25812
East Asian (EAS)
AF:
0.00
AC:
0
AN:
39250
South Asian (SAS)
AF:
0.00
AC:
0
AN:
84302
European-Finnish (FIN)
AF:
0.00
AC:
0
AN:
51224
Middle Eastern (MID)
AF:
0.00
AC:
0
AN:
5648
European-Non Finnish (NFE)
AF:
0.00000271
AC:
3
AN:
1107364
Other (OTH)
AF:
0.00
AC:
0
AN:
59886
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.492
Heterozygous variant carriers
0
0
1
1
2
2
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance
GnomAD4 genome
Cov.:
33
Alfa
AF:
0.00
Hom.:
0
ExAC
AF:
0.00000829
AC:
1

ClinVar

Significance: Conflicting classifications of pathogenicity
Submissions summary: Uncertain:4Benign:1
Revision: criteria provided, conflicting classifications
LINK: link

Submissions by phenotype

Tuberous sclerosis 2 Uncertain:1Benign:1
Nov 07, 2021
Genome-Nilou Lab
Significance:Uncertain significance
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Nov 09, 2024
Labcorp Genetics (formerly Invitae), Labcorp
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Tuberous sclerosis syndrome Uncertain:1
Jul 10, 2024
All of Us Research Program, National Institutes of Health
Significance:Uncertain significance
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This missense variant replaces serine with asparagine at codon 660 of the TSC2 protein. Computational prediction suggests that this variant may not impact protein structure and function (internally defined REVEL score threshold <= 0.5, PMID: 27666373). To our knowledge, functional studies have not been reported for this variant. This variant has not been reported in individuals affected with TSC2-related disorders in the literature. This variant has not been identified in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. -

not provided Uncertain:1
Apr 23, 2018
Eurofins Ntd Llc (ga)
Significance:Uncertain significance
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Hereditary cancer-predisposing syndrome Uncertain:1
Jan 14, 2025
Ambry Genetics
Significance:Uncertain significance
Review Status:criteria provided, single submitter
Collection Method:clinical testing

The p.S660N variant (also known as c.1979G>A), located in coding exon 18 of the TSC2 gene, results from a G to A substitution at nucleotide position 1979. The serine at codon 660 is replaced by asparagine, an amino acid with highly similar properties. This amino acid position is well conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
0.11
BayesDel_addAF
Uncertain
0.032
T
BayesDel_noAF
Benign
-0.19
CADD
Benign
18
DANN
Benign
0.86
DEOGEN2
Uncertain
0.49
T;.;.;.;.;.;.;.;.;.;.;.;T;.;T
Eigen
Benign
-0.49
Eigen_PC
Benign
-0.42
FATHMM_MKL
Benign
0.57
D
LIST_S2
Uncertain
0.94
D;D;D;D;D;D;D;D;D;D;D;D;D;D;D
M_CAP
Uncertain
0.18
D
MetaRNN
Benign
0.15
T;T;T;T;T;T;T;T;T;T;T;T;T;T;T
MetaSVM
Benign
-0.61
T
MutationAssessor
Benign
0.90
L;.;.;.;L;L;.;.;.;L;.;L;.;.;.
PhyloP100
2.9
PrimateAI
Benign
0.40
T
PROVEAN
Benign
-0.92
N;.;.;N;.;N;.;.;N;N;.;.;.;.;N
REVEL
Benign
0.27
Sift
Benign
0.30
T;.;.;T;.;T;.;.;T;T;.;.;.;.;T
Sift4G
Uncertain
0.023
D;.;.;D;.;D;.;.;D;D;.;.;.;.;D
Polyphen
0.081
B;.;.;.;B;B;.;.;B;B;.;.;.;.;.
Vest4
0.25
MutPred
0.22
Loss of glycosylation at S660 (P = 0.0016);Loss of glycosylation at S660 (P = 0.0016);Loss of glycosylation at S660 (P = 0.0016);.;Loss of glycosylation at S660 (P = 0.0016);Loss of glycosylation at S660 (P = 0.0016);Loss of glycosylation at S660 (P = 0.0016);Loss of glycosylation at S660 (P = 0.0016);.;Loss of glycosylation at S660 (P = 0.0016);Loss of glycosylation at S660 (P = 0.0016);Loss of glycosylation at S660 (P = 0.0016);Loss of glycosylation at S660 (P = 0.0016);Loss of glycosylation at S660 (P = 0.0016);.;
MVP
0.81
ClinPred
0.25
T
GERP RS
5.5
Varity_R
0.070
gMVP
0.32
Mutation Taster
=95/5
polymorphism

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.11
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs754504918; hg19: chr16-2121817; API